Archives of Dermatological Research

, Volume 297, Issue 6, pp 249–255 | Cite as

The changes in expression of ICAM-3, Ki-67, PCNA, and CD31 in psoriatic lesions before and after methotrexate treatment

  • Ayca Cordan Yazici
  • Umit Tursen
  • Duygu Dusmez Apa
  • Guliz Ikizoglu
  • Hale Api
  • Kiymet Baz
  • Bahar Tasdelen
Original Paper


Although the effectiveness of methotrexate (MTX) in the treatment of psoriasis is very well established, the mechanism of action is poorly understood. It was suggested that the therapeutic effect of MTX in psoriasis might be mediated by inhibition of adhesion molecule expression. The aim of our study was to investigate the different effects of MTX treatment on cell proliferation, inflammatory infiltrate, adhesion molecules, and angiogenesis in psoriasis, and to clarify the mechanism by which MTX exerts its therapeutic effects. Clinical response, the morpho–phenotypic changes, epidermal thickness, and mitosis count were analyzed and the expression of CD31 and ICAM-3, proliferative markers such as Ki-67, PCNA, were evaluated by immunohistochemical techniques in lesional psoriatic epidermis, before and after the treatment with MTX in ten patients. In posttreatment biopsies a decrease in the degree of epidermal hyperplasia and a significant reduction in the severity of the inflammatory infiltrate (P<0.05) were observed. In addition, CD31 and ICAM-3 expression was significantly decreased on dermal cellular infiltrate, (respectively; P<0.05, P<0.01). Ki67 and PCNA expression were suppressed concurrently in about 90% of cases (P<0.01). We suggest that MTX may have an inhibitory effect on an initial integral component of the pathways that lead to psoriasis. Immunopharmacologic intervention in adhesion event has the potential to improve psoriasis. Inhibition of revascularization may be another mechanism of action of MTX.


Psoriasis ICAM-3 CD31 Ki-67 PCNA Methotrexate 


  1. 1.
    Babina M, Mammeri K, Henz BM (2001) Retinoic acid up-regulates myeloid ICAM-3 expression and function in a cell-specific fashion-evidence for retinoid signaling pathways in the mast cell lineage. J Leukoc Biol 69:361–372PubMedGoogle Scholar
  2. 2.
    Baker BS, Swain AF, Valdimarsson H, Fry L (1984) T-cell subpopulations in the blood and skin of patients with psoriasis. Br J Dermatol 110:37–44PubMedCrossRefGoogle Scholar
  3. 3.
    Barker JN, MacDonald DM (1992) Cutaneous lymphocyte trafficking in the inflammatory dermatoses. Br J Dermatol 126:211–215PubMedCrossRefGoogle Scholar
  4. 4.
    Berti E, Cerri A, Marzano AV et al (1998) Mometasone furoate decreases adhesion molecule expression psoriasis. Eur J Dermatol 8:421–426PubMedGoogle Scholar
  5. 5.
    Bjerring P, Beck HI, Zachariae H, Sogaard H (1986) Topical treatment of psoriatic skin with methotrexate cream: a clinical, pharmacokinetic, and histological study. Acta Derm Venereol 66:515–519PubMedGoogle Scholar
  6. 6.
    de Boer OJ, Wakelkamp IM, Pals ST et al (1994) Increased expression of adhesion receptors in both lesional and non-lesional psoriatic skin. Arch Dermatol Res 286:304–311CrossRefPubMedGoogle Scholar
  7. 7.
    Bogen S, Pak J, Garifallou M et al (1994) Monoclonal antibody to murine PECAM-1 (CD31) blocks acute inflammation in vivo. J Exp Med 179:1059–1064CrossRefPubMedGoogle Scholar
  8. 8.
    Cao G, O’Brien CD, Zhou Z et al (2002) Involvement of human PECAM-1 in angiogenesis and in vitro endothelial cell migration. Am J Physiol Cell Physiol 282:1181–1190Google Scholar
  9. 9.
    Ciesielski CJ, Pflug JJ, Mei J, Piccinini LA (1998) Methotrexate regulates ICAM-1 expression in recipients of rat cardiac allografts. Transpl Immunol 6:111–121CrossRefPubMedGoogle Scholar
  10. 10.
    Creamer D, Allen MH, Sousa A et al (1997) Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. Br J Dermatol 136:859–865CrossRefPubMedGoogle Scholar
  11. 11.
    Dolhain RJ, Tak PP, Dijkmans BA et al (1998) Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br J Rheumatol 37:502–508CrossRefPubMedGoogle Scholar
  12. 12.
    Dommann SN, Dommann-Scherrer CC, Ziegler T et al (1997) Expression of intercellular adhesion molecule 3 (CDw50) on endothelial cells in cutaneous lymphomas. Am J Dermatopathol 19:391–395CrossRefPubMedGoogle Scholar
  13. 13.
    Griffiths CE, Railan D, Gallatin WM, Cooper KD (1995) The ICAM-3 / LFA-1 interaction is critical for epidermal Langerhans cell alloantigen presentation to CD4+ T cells. Br J Dermatol 133:823–829PubMedCrossRefGoogle Scholar
  14. 14.
    Griffiths CE, Boffa MJ, Gallatin WM, Martin S (1996) Elevated levels of circulating intercellular adhesion molecule-3 (cICAM-3) in psoriasis. Acta Derm Venereol 76:2–5PubMedGoogle Scholar
  15. 15.
    Groves RW, Allen MH, Barker JN et al (1991) Endothelial leucocyte adhesion molecule-1 (ELAM-1) expression in cutaneous inflammation. Br J Dermatol 124:117–123PubMedCrossRefGoogle Scholar
  16. 16.
    Groves RW, Ross EL, Barker JN, MacDonald DM (1993) Vascular cell adhesion molecule-1: expression in normal and diseased skin and regulation in vivo by interferon. J Am Acad Dermatol 29:67–72PubMedCrossRefGoogle Scholar
  17. 17.
    Hannuksela-Svahn A, Pääkkö P, Autio P et al (1999) Expression of p53 protein before and after PUVA treatment in psoriasis. Acta Derm Venereol 79:195–199CrossRefPubMedGoogle Scholar
  18. 18.
    Heenen M, Laporte M, Noel JC, de Graef C (1998) Methotrexate induces apoptotic cell death in human keratinocytes. Arch Dermatol Res 290:240–245CrossRefPubMedGoogle Scholar
  19. 19.
    Heydendael VM, Spuls PI, Opmeer BC et al (2003) Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 349:658–665CrossRefPubMedGoogle Scholar
  20. 20.
    Hirata S, Matsubara T, Saura R et al (1989) Inhibition of in vitro vascular endothelial cell proliferation by low-dose methotrexate. Arthritis Rheum 32:1065–1073PubMedCrossRefGoogle Scholar
  21. 21.
    Horrocks C, Duncan JI, Oliver AM, Thomson AW (1991) Adhesion molecule expression in psoriatic skin lesions and the influence of cyclosporin A. Clin Exp Immunol 84:157–162PubMedCrossRefGoogle Scholar
  22. 22.
    Ilan N, Madri JA (2003) PECAM-1: old friend, new partners. Curr Opin Cell Biol 15:515–524CrossRefPubMedGoogle Scholar
  23. 23.
    Johnston A, Gudjonsson JE, Sigmundsdottir H et al (2005) The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 114:154–163CrossRefPubMedGoogle Scholar
  24. 24.
    Kane D, Gogarty M, O’Leary J et al (2004) Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis Rheum 50:3286–3295CrossRefPubMedGoogle Scholar
  25. 25.
    Kowalzick L, Bildau H, Neuber K et al (1993) Clinical improvement in psoriasis during dithranol /UVB therapy does not correspond with a decrease in elevated serum soluble ICAM-1 levels. Arch Dermatol Res 285:233–235CrossRefPubMedGoogle Scholar
  26. 26.
    Kowalzick L, Neuber K, Weichenthal M et al (1994) Elevated serum-soluble ELAM-1 levels in patients with severe plaque-type psoriasis. Arch Dermatol Res 286:414–416CrossRefPubMedGoogle Scholar
  27. 27.
    Krueger JG (2002) The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46:1–23CrossRefPubMedGoogle Scholar
  28. 28.
    Lisby S, Ralkiaer E, Rothlein R, Vejlsgaard GL (1989) Intercellular adhesion molecule-1 (ICAM-1) expression correlated to inflammation. Br J Dermatol 120:479–484PubMedCrossRefGoogle Scholar
  29. 29.
    Manara GC, Pasquinelli G, Badiali-De Giorgi L et al (1996) Human epidermal Langerhans cells express the ICAM-3 molecule. Immunohistochemical and immunoelectron microscopical demonstration. Br J Dermatol 134:22–27CrossRefPubMedGoogle Scholar
  30. 30.
    Marks R, Barton SP, Shuttleworth D, Finlay AY (1989) Assesment of disease progress in psoriasis. Arch Dermatol 125:235–240CrossRefPubMedGoogle Scholar
  31. 31.
    Miracco C, Pellegrino M, Flori ML et al (2000) Cyclin D1, B and A expression and cell turnover in psoriatic skin lesions before and after cyclosporin treatment. Br J Dermatol 143:950–956CrossRefPubMedGoogle Scholar
  32. 32.
    Muller WA, Weigl SA, Deng X, Phillips DM (1993) PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med 178:449–460CrossRefPubMedGoogle Scholar
  33. 33.
    Onuma S (1994) Immunohistochemical studies of infiltrating cells in early and chronic lesions of psoriasis. J Dermatol 21:223–232PubMedGoogle Scholar
  34. 34.
    Pestelli E, Floriani I, Fabbri P, Caproni M (2003) Cetirizine modulates adhesion molecule expression in a double-blind controlled study conducted in psoriatic patients. Int J Tissue React 25:1–8PubMedGoogle Scholar
  35. 35.
    Piskin G, Heydendael VM, de Rie MA et al (2003) Cyclosporin A and methotrexate are equally effective in reducing T cell numbers in psoriatic skin lesions but have no consistent effect on IFN-gamma and IL-4 expression in psoriatic skin in situ. Arch Dermatol Res 294:559–562PubMedGoogle Scholar
  36. 36.
    Rentenaar RJ, Heydendael VM, van Diepen FN et al (2004) Systemic treatment with either cyclosporin A or methotrexate does not influence T helper 1/T helper 2 balance in psoriatic patients. J Clin Immunol 24:361–369CrossRefPubMedGoogle Scholar
  37. 37.
    Savoia P, Novelli M, De Matteis A et al (1998) Effect of topical calcipotriol on the expression of adhesion molecules in psoriasis. J Cutan Pathol 25:89–94PubMedCrossRefGoogle Scholar
  38. 38.
    Servitje O, Bordas X, Seron D et al (1996) Changes in T-cell phenotype and adhesion molecules expression in psoriatic lesions after low-dose cyclosporin therapy. J Cutan Pathol 23:431–436PubMedCrossRefGoogle Scholar
  39. 39.
    Sigmundsdottir H, Johnston A, Gudjonsson JE et al (2004) Methotrexate markedly reduces the expression of vascular E-selectin, cutaneous lymphocyte-associated antigen and the numbers of mononuclear leucocytes in psoriatic skin. Exp Dermatol 13:426–434CrossRefPubMedGoogle Scholar
  40. 40.
    Stewart WD, Wallace SM, Runikis JO (1972) Absorption and local action of methotrexate in human and mouse skin. Arch Dermatol 106:357–361CrossRefPubMedGoogle Scholar
  41. 41.
    Terajima S, Higaki M, Igarashi Y et al (1998) An important role of tumor necrosis factor-α in the induction of adhesion molecules in psoriasis. Arch Dermatol Res 290:246–252CrossRefPubMedGoogle Scholar
  42. 42.
    Thomson AW, Nalesnik M, Abu-Elmagd K, Starzl TE (1991) Influence of FK506 on T lymphocytes, Langerhans’ cells and the expression of cytokine receptors and adhesion molecules in psoriatic skin lesions: a preliminary study. Transplant Proc 23:3330–3331PubMedGoogle Scholar
  43. 43.
    Vaporciyan AA, DeLisser HM, Yan HC et al (1993) Involvement of platelet endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. Science 262:1580–1582PubMedCrossRefGoogle Scholar
  44. 44.
    Wakita H, Takigawa M (1994) E-selectin and vascular cell adhesion molecule-1 are critical for initial trafficking of helper-inducer/memory T cells in psoriatic plaques. Arch Dermatol 130:457–463CrossRefPubMedGoogle Scholar
  45. 45.
    Wong MX, Roberts D, Bartley PA, Jackson DE (2002) Absence of platelet endothelial cell adhesion molecule-1 (CD31) leads to increased severity of local and systemic IgE-mediated anaphylaxis and modulation of mast cell activation. J Immunol 168:6455–6462PubMedGoogle Scholar
  46. 46.
    Yamasaki E, Soma Y, Kawa Y, Mizoguchi M (2003) Methotrexate inhibits proliferation and regulation of the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by cultured human umbilical vein endothelial cells. Br J Dermatol 149:30–38CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Ayca Cordan Yazici
    • 1
  • Umit Tursen
    • 1
  • Duygu Dusmez Apa
    • 2
  • Guliz Ikizoglu
    • 1
  • Hale Api
    • 1
  • Kiymet Baz
    • 1
  • Bahar Tasdelen
    • 3
  1. 1.Departments Of DermatologyMersin University, School of MedicineMersinTurkey
  2. 2.Departments Of PathologyMersin University, School of MedicineMersinTurkey
  3. 3.Departments Of BiostatisticsMersin University, School of MedicineMersinTurkey

Personalised recommendations